Lymph Node Metastasis in Papillary Thyroid Carcinoma, A Study of BRAF V600E and TERT Promoter Mutations

Soeratman, Alif Rizky; Kartini, Diani; Andinata, Bob; Harahap, Agnes Stephanie; Sudarsono, Nani Cahyani

doi:10.31557/APJCP.2024.25.6.2043

Lymph Node Metastasis in Papillary Thyroid Carcinoma, A Study of BRAF V600E and TERT Promoter Mutations

Document Type : Research Articles

Authors

¹ Surgical Oncology Division, Department of Surgery, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

² Department of Surgical Oncology, Dharmais National Cancer Center Hospital, Jakarta, Indonesia.

³ Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

⁴ Department of Anatomical Pathology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

⁵ Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

10.31557/APJCP.2024.25.6.2043

Abstract

Objective: This study was designed to determine the role of BRAF V600E and TERT mutations in the incidence of neck lymph node (LN) metastasis in patients with papillary thyroid carcinoma (PTC). Methods: This was a cross-sectional study, involving PTC patients at Dr. Cipto Mangunkusumo Hospital, Jakarta. Data were obtained retrospectively based on medical records, except for BRAF V600E and TERT promoter mutations. Tumor tissue specimens of PTC’s patients were transferred to the Integrated Laboratory of Faculty of Medicine, Universitas Indonesia. BRAF gene multiplication was performed with KOD One PCR Master Mix (Toyobo KMM-201), while TERT gene multiplication was performed with PCR Master Mix. Data analysis was performed with SPSS version 20. The data were analyzed using univariate and bivariate analysis with the Chi-Square test. Result: 42 PTC patients were included in the study; 19 (45%) had BRAF mutation, 20 (48%) had TERT mutation, and 20 (48%) had LN metastases. BRAF V600E mutation was associated with LN metastasis [p<0.001, OR = 25.33 (95% CI 4.92 – 130.34)], while TERT mutation was not. Patients with BRAF+ and TERT- mutations were 18.00 times (95% CI 2.01 - 161.05) more likely to develop LN metastasis than patients with BRAF- and TERT-. Furthermore, the presence of TERT mutation along with BRAF mutation increased the risk to 60.00 (95% CI 4.72 – 763.04) higher than patients with BRAF- and TERT-. Conclusion: BRAF mutation was associated with LN metastasis in PTC patients, but not TERT mutations. However, the presence of TERT mutation in PTC’s patients with BRAF mutation increased the risk of LN metastasis.

Keywords